Profound thrombocytopenia in previously treated patients with recurrent ovarian carcinoma receiving topotecan (multiple letters)

Gynecologic Oncology

Volumn 69, Issue 2, 1998, Pages 175-176

  Cass, I ^a   Kuo, D Y ^a   Fields, A L ^a   Runowicz, C D ^a   Goldberg, G L ^a   Abendstein, B ^a   Klingler, P J ^a   Sevin, B U ^a   Posner, J B ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR; TOPOTECAN;

ADULT; ANTIBODY TITER; BONE MARROW TOXICITY; BRAIN INFARCTION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; FEMALE; HUMAN; LETTER; NEUTROPENIA; OVARY CARCINOMA; PARANEOPLASTIC SYNDROME; PRIORITY JOURNAL; RECURRENT CANCER; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

EID: 0031860557     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1998.4966     Document Type: Editorial

References (3)

1. EK Rowinsky LB Grochow CB Hendricks DS Ettinger AA Forastiere LA Hurowitz WP McGuire SE Sartorius BG Lubejko SH Kaufmann RC Donehower Phase I pharmacologic study of Topotecan: A novel topoisomerase inhibitor J Clin Oncol 10 1992 647 656
2. AP Kudelka D Tresukosol CL Edwards RS Freedman C Levenback P Chantarawiroj C Gonzalez de Leon EE Kim T Madden B Wallin M Hord C Verschraegen M Raber JJ Kavanagh Phase II study of intravenous Topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma J Clin Oncol 14 1996 1552 1557
3. W ten Bokkel Huinink M Gore G Bolis J Verweij J Lacave G Scarfone J Guastalla S Van Belle R Despax G Favalli I Hudson A Kreinberg Phase II trial of topotecan for the treatment of relapsed advanced ovarian carcinoma Proc Am Soc Clin Oncol 15 May 1996 284